Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
It is used to manage alcoholic fatty liver (disease that occurs due to heavy alcohol use), liver fibrosis/cirrhosis (scarring of liver due to excessive consumption of alcohol), and hepatitis (inflammation of liver) in affected individuals
Due to semaglutide's already-long half-life, the benefit of daily over thrice-weekly dosing is minimal
Safety Comparison# Semaglutide# Well-characterized safety profile across thousands of patients: GI adverse events: 50-70% (mostly mild-moderate, dose-escalation related) Discontinuation due to AEs: ~7% (STEP 1) Boxed warning: Thyroid C-cell tumors (rodent data) Post-marketing signals: Pancreatitis, gallbladder events, ileus (rare) 8+ years of post-marketing surveillance Zovaglutide# Phase 2 safety data (303 patients, 24 weeks): GI adverse events: Present but low severity Discontinuation due to GI AEs: 1.3% (notably low for GLP-1 class) Monthly dosing showed fewer GI events than biweekly dosing No long-term safety data available No post-marketing experience The 1.3% GI-related discontinuation rate is notably lower than typical GLP-1 agonists (5-10%)
This could indicate that your dose needs adjustment or that you need additional support
10.2337/diab.45.6.832 103
Once prescribed by one of Get Slimss network of licensed healthcare professionals, compounded semaglutide is self-injected just once a week
